In the study, NeuroVive is evaluating the advanced CicloMulsion cremophor-free IV cyclosporine formulation in 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction to examine cyclosporine’s ability to protect cardiac tissue.
The impact of cyclosporine will be investigated against a number of objective clinical parameters, including left ventricular function, blood markers of myocardial infarction, quantitative assessment of myocardial infarction size, and clinical status of the patient after completion of PCI.
NeuroVive expects to recruit patients at 40 centers in France and additional European sites.
NeuroVive’s CEO Mikael Bronnegard said if efficacy is proven, NeuroVive’s CicloMulsion, a safe formulation of cyclosporine, should become an important new treatment for heart patients and reduce morbidity and mortality after myocardial infarction.